{"id":"NCT05362058","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time","officialTitle":"A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Na√Øve Adults With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-06-03","primaryCompletion":"2024-04-10","completion":"2024-04-10","firstPosted":"2022-05-05","resultsPosted":"2025-05-16","lastUpdate":"2025-05-16"},"enrollment":928,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Insulin Efsitora Alfa","otherNames":["LY3209590 and Basal Insulin-FC"]},{"type":"DRUG","name":"Insulin Degludec","otherNames":[]}],"arms":[{"label":"500 U/mL - Insulin Efsitora Alfa","type":"EXPERIMENTAL"},{"label":"100 U/mL - Insulin Degludec","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the effect and safety of insulin efsitora alfa (LY3209590) compared to degludec in adult participants with type 2 diabetes who are starting basal insulin for the first time. The study consists of a 1-week screening period, a 2-week lead-in period, a 52-week treatment period, and a 5-week safety follow-up period. The study will last up to 60 weeks.","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 52 [Noninferiority Analysis]","timeFrame":"Baseline, Week 52","effectByArm":[{"arm":"500 U/mL - Insulin Efsitora Alfa","deltaMin":-1.26,"sd":0.047},{"arm":"100 U/mL - Insulin Degludec","deltaMin":-1.17,"sd":0.0473}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":113,"countries":["United States","Brazil","Canada","China","Czechia","Germany","Greece","Japan","Mexico","Puerto Rico","South Korea"]},"refs":{"pmids":["39254740"],"seeAlso":["https://trials.lilly.com/en-US/find/completed?trialname=%20I8H-MC-BDCX&externalRequestID=68cbce79-fbf1-46c5-852a-338ca6e2be85"]},"adverseEventsSummary":{"seriousAny":{"events":41,"n":466},"commonTop":["Covid-19","Drug titration error","Nasopharyngitis","Upper respiratory tract infection","Diarrhoea"]}}